20-F/A: BioLineRx Amends 20-F Filing to Correct Typographical Error
Annual Report Amendment
BioLineRx files an amendment to its 20-F report to correct a typographical error in the independent auditor's report and re-file an exhibit.
Summary
- BioLineRx has amended its annual report on Form 20-F for the year ended December 31, 2023, to correct a typographical error in the report of its independent registered public accounting firm.
- The amendment also includes a re-filing of Exhibit 2.1 from the original report.
- New certifications by the principal executive officer and principal financial officer are included as exhibits.
- A new consent from the independent registered public accounting firm is also filed.
- The amendment does not reflect events occurring after the filing of the original report and does not modify or update the disclosure therein in any way except as described above or herein.
Sentiment
Score: 7
Explanation: The document is a routine regulatory filing, so the sentiment is neutral. The correction of an error is a positive sign of attention to detail.
Future Outlook
The document does not contain any future outlook statements.
Industry Context
This is a standard regulatory filing update, not directly related to industry trends but necessary for maintaining compliance and transparency with investors.
Key Dates
| Date | Description |
|---|---|
| 2003 | BioLineRx was founded |
| 2007-02 | Completed initial public offering in Israel |
| 2011-07 | Listed ADSs on Nasdaq |
| 2017-03 | Acquired Agalimmune Ltd. |
| 2023-08-27 | Entered into a License Agreement with Hong Seng Technology Limited and Guangzhou Gloria Biosciences Co., Ltd. |
| 2023-09-08 | FDA approved motixafortide |
| 2023-12-31 | End of fiscal year |
| 2024-03-15 | Effective date of termination of Agalimmune Development Agreement |
| 2024-03-26 | Date of filing of the amended 20-F report |
Keywords
20-F, amendment, BioLineRx, financial reporting, auditor's report, Kesselman & Kesselman
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.